Program Agenda

A conference of the MIT Laboratory for Financial Engineering

In collaboration with the National Cancer Institute
and with the participation of the American Cancer Society
and the American Association for Cancer Research

Dedicated to the Memory of Thomas A. Tombrello

October 26-28, 2014
Cambridge, MA

CanceRx 2014 is an invitation-only conference hosted by MIT focusing exclusively on new approaches to financing biomedical innovation in oncology and other areas. The conference will bring together representatives from key stakeholder communities including academia and medical research centers, community hospitals, the biopharma industry, health plans, NIH/NCI, the FDA, patient advocacy groups, investment banks, hedge funds, credit rating agencies, biotech VCs, and institutional and retail investors.

The conference will be organized as a series of panel discussions—with substantial audience participation—devoted to addressing the funding challenges facing academia and the biopharma industry, including:

  • Updates on fundraising initiatives and their business models since CanceRX 2013
  • Recent scientific and clinical breakthroughs and potential business implications
  • Financial modeling techniques for managing biopharma assets and liabilities
  • Innovations in intellectual property rights management and licensing structures
  • The changing role of government, patient advocacy groups, and philanthropy

In addition, an optional executive education program, “Basic Financial Analysis for Life Sciences Professionals,” will be offered from 1:00 to 5:00pm on Sunday October 26, followed by the welcome dinner at 6:00pm. Space for this educational program is limited to 100 participants on a first-come-first-served basis.[This text is here for extra space]

pdf_icon Downloadable Agenda

Sunday, October 26
1:00 – 5:00 Optional Executive Education Program: “Financial Analysis for Life Sciences Professionals”
Andrew W. Lo, MIT
MIT Sloan School of Management, 2nd Floor, 100 Main Street (Building E62), Cambridge, MA 02142
Space is limited to 100 participants on a first-come-first-served basis.
5:00 – 6:00 Registration and Cocktails
Boston Marriott Cambridge, 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142
6:00 – 8:00 Welcome Dinner
Keynote Speaker: Clifton Leaf, Fortune
Introduction by Marty Tenenbaum, Cancer Commons
Monday, October 27
Boston Marriott Cambridge, 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142
8:00 – 8:30 Continental Breakfast and Registration
8:30 – 9:00 Welcome and Conference Background and Objectives
David Schmittlein, MIT
Andrew W. Lo, MIT
9:00 – 10:30 Session 1: Scientific Advances and Challenges
Parag Mallick*, Stanford University; Stephen Fawell, AstraZeneca; Michael Goldberg, Dana-Farber Cancer Institute; Tyler Jacks, Koch Institute for Integrative Cancer Research at MIT; Manolis Kellis, MIT; and Phillip Sharp, MIT
10:30 – 11:00 Break
11:00 – 12:30 Session 2: Re-Engineering the Drug Discovery Process
Alan Jakimo*, Sidley Austin LLP; Christopher Austin, NCATS; Gary Kelloff, NCI; Cyrus Mehta, Cytel; Robert O’Neill, FDA; Azita Sharif, Daedalus Software
12:30 – 2:00 Lunch
Keynote Speakers: Judy Lewent and Cathrin Petty, J.P. Morgan
Introduction by Stewart C. Myers, MIT
2:00 – 3:30 Session 3: New and Emerging Business Models
Greg Simon*, Poliwogg; Duncan Darrow, New Fund Institute; Ilan Ganot, Solid Ventures; Edward Jung, Intellectual Ventures; Tom Rutledge, Magnetar Capital; Jake Xia, Harvard Management Company
3:30 – 4:00 Break
4:00 – 5:30 Session 4: Funding, Structuring, and Investor Perspectives, Part 1
Jose Maria Fernandez*, Spanish Treasury, Ministry for the Economy and Competition; Doug Dachille, First Principles Capital Management; Sandra M. Forman, Proskauer; Alison Li, CalPERS; Rosemarie Loffredo, Leukemia & Lymphoma Society; Anna Makki, Credit Suisse
5:30 – 6:00 Day 1 Conference Wrap-Up
6:00 Dinner
Keynote Speaker: Pablo Legorreta, Royalty Pharma
Introduction by S. P. Kothari, MIT
Tuesday, October 28
Boston Marriott Cambridge, 2nd Floor Salons, 2 Cambridge Center (50 Broadway), Cambridge, MA 02142
8:00 – 8:30 Continental Breakfast
8:30 – 10:00 Session 5: Innovations from Big Pharma
Monique Mansoura*, Novartis; Ann Dewitt, Sanofi-Genzyme Bioventures; Jose-Carlos Gutierrez-Ramos, Pfizer; Jeb Keiper, Nimbus Discovery; Juan Carlos Lopez, Roche; Darren Snellgrove, Johnson & Johnson Innovation
10:00 – 10:30 Break
10:30 – 12:00 Session 6: Economics of Biomedical Innovation
Andrew W. Lo*, MIT; Rena Conti, University of Chicago; Joseph Dimasi, Tufts Center for the Study of Drug Development; Bruce Lehmann, University of California, San Diego; Tom Philipson, University of Chicago; Vikas Sukhatme, Beth Israel Deaconess
12:00 – 1:30 Lunch
Keynote Speaker: Eric Lander, The Broad Institute
Introduction by Larry Norton, Memorial Sloan Kettering Cancer Center
1:30 – 3:00 Session 7: Funding, Structuring, and Investor Perspectives, Part 2
Roger Stein*; Francois Boissel, Novadiscovery; John Frishkopf, NewStar Financial; Michael Millette, Goldman Sachs; Issi Rozen, The Broad Institute; David Sabow, Silicon Valley Bank
3:00 – 3:30 Break
3:30 – 5:00 Session 8: The Role of Government, Patient Advocacy, and Philanthropy
Doug Criscitello*, Grant Thornton; Karen Shaw Petrou, Federal Financial Analytics; Syril Pettit, ILSI Health and Environmental Sciences Institute; Leslie Platt, Innovation Financing Roundtable; Kenneth Schaner, Schaner & Lubitz; Christiana Stamoulis, Hologic, Inc.
5:00 – 5:30 Day 2 Conference Wrap-Up

* Session Moderator